Mesa Laboratories (MLAB) director buys 1,301 shares in open-market trade

Rhea-AI Filing Summary

Mesa Laboratories director Mark Christopher Capone bought additional company stock in an open-market transaction. He purchased 1,301 shares of Common Stock at a price of $76.35 per share. After this purchase, he directly owns 3,429 shares of Mesa Laboratories Common Stock.

Insights

Equity ownership analyst

Director makes a modest open-market share purchase, slightly increasing direct ownership.

Director Mark Christopher Capone acquired 1,301 Mesa Laboratories common shares in an open-market transaction at $76.35 per share. Open-market purchases typically reflect a deliberate decision to commit personal capital, as opposed to receiving shares through compensation grants.

Following the transaction, Capone holds 3,429 shares directly. The filing does not show any related derivative positions, suggesting this transaction is a straightforward cash equity purchase rather than part of an options exercise. Overall, it appears as a routine insider buy of limited scale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capone Mark Christopher

(Last) (First) (Middle)

320 WAKARA WAY

(Street)

SALT LAKE CITY UT 84108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P		1,301	A	$76.35	3,429	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	John Sakys under Power of Attorney by Mark Capone	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mesa Laboratories (MLAB) report for Mark Christopher Capone?

Mesa Laboratories reported that director Mark Christopher Capone bought 1,301 shares of Common Stock. The open-market purchase was executed at $76.35 per share, increasing his direct ownership position in the company’s stock as disclosed in the Form 4 filing.

At what price did the Mesa Laboratories (MLAB) director buy shares?

The director purchased Mesa Laboratories Common Stock at $76.35 per share. This price reflects an open-market transaction, meaning he chose to commit personal capital at prevailing market levels rather than receiving the shares through compensation or option exercises.

How many Mesa Laboratories (MLAB) shares does Mark Christopher Capone own after this transaction?

After the reported transaction, Mark Christopher Capone directly owns 3,429 shares of Mesa Laboratories Common Stock. This total reflects his holdings following the 1,301-share open-market purchase disclosed in the Form 4 insider trading report filed with regulators.

Was the Mesa Laboratories (MLAB) insider trade a buy or a sell?

The reported Mesa Laboratories insider trade was a buy. Director Mark Christopher Capone executed an open-market purchase of 1,301 Common Stock shares, as indicated by transaction code “P” and the filing’s classification of the transaction as a net-buy event.

Did the Mesa Laboratories (MLAB) Form 4 include any option or derivative exercises?

The Form 4 does not report any option or derivative exercises for this transaction. It shows only a non-derivative open-market purchase of 1,301 Common Stock shares, with derivative-related transaction counts and derivative positions listed as zero in the summarized data.